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routinely warranted in this patient population. Patients who
require systemic corticosteroids posteHSC may be consid-
ered for PJ prophylaxis.151
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There is little consensus regarding the optimal conditioning
regimen for AHCT for NHL. Thiotepa is an alkylating agent
with anti-lymphoma properties, but it has limited data as a
conditioning agent for AHCT in adult NHL. We report here
long-term results of our institutional experience in NHL
receiving AHCT following HDT with etoposide, cyclophos-
phamide and thiotepa (VP-16/CY/TT). Patients received eto-
poside 1800mg/m2 IV x 1 dose, cyclophosphamide (50mg/
kg/dose IV x 3-4 doses), and thiotepa (250mg/m2/dose e
300mg/m2/dose x 3 doses). Forty-three patients were con-
sented and enrolled from November 1997 to June 2009.Table 1
Baseline Demographics
Characteristics N¼43
Median age, years (range) 55 (27-69)
Male gender, n (%) 22 (51%)
Diagnosis (%)
Diffuse Large B-cell Lymphoma (DLBCL) 23 (54%)
Follicular Lymphoma 7 (16%)
Transformed follicular lymphoma 2 (5%)
Mantle Cell Lymphoma 4 (9%)
T-cell NHL 7 (16%)
Bone Marrow Involvement 10 (23%)
CNS Involvement 2 (5%)
Stage
Early Stage (1&2) 14 (32%)
Advanced Stage (3&4) 27 (63%)
Missing 2 (5%)
IPI
Low (0-1) 17 (40%)
Intermediate (2-3) 23 (54%)
High (4-5) 2 (5%)
Unknown 1 (2%)
Prior therapies, median (range) 2 (1-4)
Remission status before transplant
Complete Remission 1 8 (19%)
Complete Remission 2 17 (40%)
Complete Remission 3 2 (5%)
Partial Remission 16 (37%)
Autologous stem cell source (%)
Peripheral Blood 35 (81%)
Bone Marrow 4 (9%)
Both 4 (9%)
Karnofsky Performance Status,
median (range)
90 (80-100)
Median CD34 cell dose infused (106 cells/kg
recipient), (range)
5.3 (1.8-10.5)Disease characteristics are described in Table 1. Peripheral
blood stem cell mobilization utilized cyclophosphamide
and ﬁlgrastim. All patients received antibacterial, antiviral
(acyclovir), and antifungal (ﬂuconazole) prophylaxis along
with ﬁlgrastim support after stem cell infusion. Median
follow up for surviving patients was 4.7 years (range 0.26
years to 15.85 years). Median time to neutrophil and platelet
engraftment was 13 and 21 days, respectively. Signiﬁcant
regimen-related toxicities included mucositis (51%), neu-
tropenic fever (72%), diarrhea (26%), and pneumonia (9%).
No CNS failures were reported. Secondary malignancies
occurred in 3 patients (7%) e two of which were soft tissue
sarcomas and one MDS/AML. Progression free survival (PFS)
and overall survival (OS) at 5 years was 53% (39% - 71%) and
73% (60% - 89%), respectively. Relapse rates at day +100 and 5
years were 9.4% (95% CI: 2.9% e 20.4%) and 40.1% (95% CI:
24.7% - 55.1%), respectively. Cumulative incidence of non-
relapse mortality at day +100 and 5 years was 4.7% (95% CI:
0.8% - 14.0%) and 7% (95% CI: 1.8% - 17.4%), respectively. VP-
16/Cy/TT is a well-tolerated conditioning regimen for pa-
tients with NHL, with promising long term progression-free
and overall survival rates.152
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We performed a retrospective analysis on patients who un-
derwent PBSC collection and subsequent ASCT at our insti-
tution to assess whether efﬁciency of PBSC mobilization is
predictive of engraftment failure.
Methods: We identiﬁed 369 patients who underwent PBSC
collection between 01/01/2006-8/31/2012 for a ﬁrst ASCT.
We collected data on age, sex, use of lenalidomide or
thalidomide (“Imid”) prior to mobilization, mobilization
regimen, # of collections for ﬁnal cell dose, # of CD34+ cells
infused, and the presence of a positive blood culture within
30 days of ASCT. Quintiles were created for the # of CD34+
cells collected. The primary outcomewas engraftment failure
deﬁned as not achieving an absolute neutrophil count (ANC)
>1000/mL or a platelet count >50,000/mL (no platelet
transfusion in </¼ 7 days) by day 30 post-ASCT. Secondary
outcomes were time to ANC and platelet engraftment. We
performed a multivariate logistic regression analysis to
assess the association of collected CD34+ cells and engraft-
ment failure while adjusting for the other variables. For time
to event analyses we used Cox proportional hazard models.
Results: Median patient age was 58 and 56% were male.
Patient-reported race was: Black (38%), White (17%), and
“Other” (45%). Indications for ASCT were Multiple Myeloma
(45%), Non-Hodgkin Lymphoma (41%), Acute Leukemia (9%),
Hodgkin Lymphoma (3%), Amyloidosis (1%), and Germ Cell
Tumors (1%). The median # of CD34+ cells collected was
7.7x10
ˇ
6/kg (range 2.26-120 x10
ˇ
6/kg) and median # of
CD34+ cells infused was 5.3x10
ˇ
6/kg (2.3-45x10
ˇ
6/kg).
Median # of collections for transplant dosewas 2 (range 1-8).
CD34 cells collected were divided into quintiles (cut points:
6.04, 7.57, 9.86 and 17.7x10
ˇ
6/kg). We found that a higher #
of collected CD34+ cells during mobilization was associated
with less engraftment failure (p¼.0067): every increase in
